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Abstract
This paper quantifies the relationship between market size and innovation in the pharmaceutical
industry using improved, and newer, methods and data. We find positive significant elasticities of
innovation to expected market size with a point estimate under our preferred specification of 0.23.
This suggests that, on average, $2.5 billion is required in additional revenue to support the invention
of one new chemical entity. This magnitude is plausible given recent accounting estimates of the
cost of innovation of 800 million to one billion per drug, and marginal costs of manufacture and
distribution near 50%. An elasticity below 1 is also a plausible implication of the hypothesis that
innovation in pharmaceuticals is becoming more difficult over time, as costs of regulatory approval
rise and as the industry runs out of ”low-hanging fruit”.
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1 Introduction
This paper quantifies the relationship between financial returns and innovation in the pharmaceutical
industry. More precisely we estimate the elasticity of innovation (as measured by the number of new
chemical entities appearing on the market for a given disease class) to the expected market size as
measured by the spending on treatment by sufferers of diseases in that class (and others acting on
their behalf such as insurers and governments). When governments engage in price regulation and
reduce prices for pharmaceutical treatments, the short run effect may be small because the innova-
tion expenditure is already sunk. However, such regulations will affect firms’ incentives to invest in
discovering new treatments. The elasticity of innovation is therefore a critical parameter to measure
in order to evaluate the cost to society of price regulation. This question has no definitive answer in
the literature due to a number of estimation difficulties that we discuss below.
In this paper we contribute what we believe to be a valuable new estimate using several novel meth-
ods. First, we have data on the global revenues of all pharmaceutical products over an eleven year
period, as collected by pharmaceutical data provider IMS. These detailed data allow us to calculate an
excellent measure of innovation, namely the number of new molecular entities released on the global
market during our time period. Much of the existing literature measures intermediate outcomes in the
innovation process such as the number of new clinical trials or available regimens. Other literature
focuses only on data from the United States. While the US is the largest and most important national
market for pharmaceutical products (with approximately 40% of demand), revenue in other nations
is large and growing and serves as an important stimulus to innovation. Global revenue data have
never, to our knowledge, been used in the literature to measure the response of innovation to market
size, yet are likely to be an important part of the incentive for firms.
Secondly, we employ new econometric methods to estimate the relationship between innovation
and market size. While a large expected market size may stimulate new pharmaceutical innovation,
it may also be the case that new pharmaceutical innovation creates sales and therefore market size.
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Innovation may also intensify competition between products and therefore reduces prices and margins.
Innovation and sales may therefore move together for two distinct reasons: first, innovation creates
sales of new products and affects the revenues on existing products, and secondly, sales stimulate
innovation. We are interested in isolating a measure of the latter. Because of the likely existence
of reverse causality, we instrument for market size in our estimation procedure using the worldwide
number of deaths from diseases in the relevant therapeutic class, as well as country GDP.
Our estimation technique is designed to obtain unbiased estimates from censored count data, as
well as accommodating our instrumental variables strategy. We find, as theory predicts, that market
size has a positive impact on global release of new molecular entities. Our elasticity estimate is sub-
stantially below unity; our preferred specification delivers an elasticity of innovation to market size of
0.25. This indicates that when a market increases in potential size by 10%, that stimulates a 2.5%
increase in the number of treatments to serve that market. The previous literature generally finds
elasticities for new drug products to be in the vicinity of 0.5, though there are exceptions which we
will discuss below. An elasticity below one could indicate the importance of competition in a market:
as the market grows and more treatments enter, margins fall. An alternative explanation is that the
fixed costs of innovation rise steeply with market size as the best ideas for treatments are sequentially
exploited. It is also possible that the previous literature’s use of US data meant that margins were
systematically higher than in our data, and this affects estimated elasticities.
We follow up this estimate with regressions specific to a therapeutic class. There is significant
variation between therapeutic classes, and the resulting average elasticity across classes is somewhat
higher than that estimated by pooling classes.
Our conceptual framework is very simple. We assume that for-profit firms in the pharmaceutical
industry choose innovation projects that they expect to be profitable. (Of course governments and
non-profits may engage in, or sponsor, research driven by other goals.) Profits will be determined
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by costs and revenues, which in turn depend on market size. Expected market size is influenced by
broadly three types of factors. First, there are factors such as demographic and socio-economic change,
which affect the numbers of people who are likely to suffer from a particular medical condition and
the resources they are likely to have available to spend on alleviating their condition. A motivating
example concerning research on gout from the New York Times illustrates the incentives for R&D.
”Often called the “disease of kings” because of its association with the rich foods and copious alcohol
once available only to aristocrats, gout is staging a middle-class comeback as American society grows
older and heavier....Companies are now racing to improve upon decades-old generic drugs that do not
work well for everyone. Already this year the Food and Drug Administration has approved the first
new gout drug in more than 40 years...”.1 Many other examples spring to mind of research motivated
primarily by changing demographic and socio-economic factors, such as research into cardiovascular
disease and Alzheimer’s disease for the overweight and aging US population. These factors have the
advantage of being exogenous to the innovation process we are investigating, and therefore measures
of this type (both demographic and GDP) will serve as our instruments.
Secondly, there are factors particular to the pharmaceutical and health-care industries, such as the
degree of competition among firms and the strategies that firms use to innovate, cut costs, and win
customers, that affect the profitability of innovation. As demonstrated in Bresnahan and Reiss (1990,
1991), increased entry increases price competition and depresses margins, making it more difficult for
the entrant to cover its fixed costs. Thus larger incremental market sizes are needed to recover the
fixed costs of innovation as the number of entrants grows. This phenomenon is likely to be magnified
in the pharmaceutical industry by the intensity of competition that brands face from generic products.
1 ”Disease of Rich Extends Its Pain to Middle class”, New York Times, June 12, 2009 . The story continued:
”...a product called Uloric from Takeda Pharmaceutical. Another new drug, Krystexxa, made by Savient Pharmaceu-
ticals of East Brunswick, N.J., will be reviewed for possible approval by an F.D.A. advisory committee on Tuesday. And
several other companies are testing drugs in clinical trials. “It’s kind of like the forgotten disease,” said Barry D. Quart,
chief executive of one of those companies, Ardea Biosciences of San Diego. Ardea discovered accidentally that an AIDS
drug it was developing might work against gout. Now the company has shifted its focus to gout, envisioning annual sales
of $1 billion if its drug is successful. That would mean a huge increase in spending on gout medicines, which had sales of
only $53.4 million last year, according to IMS Health, a health care information company. Uloric, the drug from Takeda,
sells a daily pill for at least $4.50 compared with 10 to 50 cents for the most commonly used generic, allopurinol. It is
estimated that two million to six million Americans have gout... Various studies suggest that the number of cases in this
country has as much as doubled in the last three decades”.
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This will depend on the regulatory regime governing the ease of generic entry, and also on cost-control
pressures from managed care that incentivize generic use. Ease of entry and strong financial incentives
to use generics will reduce the expected discounted profitability of the innovation. Margins on branded
drugs due to the nature of underlying demand and buyer institutions will also affect expected market
size. Overall, factors in this second category have the possibility of being endogenous to firms’ choices
of how to innovate.
Thirdly, there are public policies, including policies towards intellectual property protection, drug
safety and testing, pricing and reimbursement, and public funding of research. Sood et al (2009)
provide a comprehensive overview of the effect of regulations on pharmaceutical revenues. Subsidies
are also important: as a matter of comparison, in 2004, research spending by NIH reached $28.5
billion while the members of the Pharmaceutical Research and Manufacturers of America report R&D
spending of about $40 billion - see CBO (2006).
Studying the impact of such policy interventions is extremely important, and sometimes these
occur in circumstances that make them ideal natural experiments (see Finkelstein 2004, and Blume-
Kohout and Sood, 2012, for illuminating examples focused on single-country legislative changes). It
is quite possible, however, that policy changes may be endogenous to the predicted rate of innovation
itself, either because public policy may feel it does not need to intervene to favor areas where innova-
tion is already coming along nicely, or because public policy likes to bask in the glow of supporting
visibly successful areas, or for any number of other reasons. Such considerations may be of particular
concern with data aggregated across many countries that could be trending in an unknown policy
direction. In this paper our dataset includes sales from fourteen countries over twelve years.
For these reasons, we think it particularly useful to study factors of the first type, which are rarely
under the influence of either government or industry participants. We exploit these exogenous changes
in potential demand to estimate elasticities of innovation, which we think are a clean measures of the
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causal impact of market size on innovation. The empirical section of the paper examines the response
of global new drug launches to global expected market size measured in revenues and instrumented
with demographics. Our identification strategy is as follows. If the cardiovascular market is expected
to grow due to an aging population, firms will want to serve that demand. Firms have rational
expectations concerning demand, the actions of rivals, and the timing of innovation and regulatory
approval. Therefore, there will be an increase in cardiovascular R&D before the demand materializes
and - on average - we will see the release of new cardiovascular products on the market at the time
of the demand increase. Different therapeutic markets whose potential sizes change differently over
time due to demographic and income differences drive commensurate changes in innovative activity.
We can measure the elasticity of new products to expected market size using this variation.
Thus our instruments are GDP and measures of population and mortality from disease in our
sample of countries over time. Our strategy is sensible because, as our estimates show, demographics
are strongly correlated with revenue. Moreover, the invention of a new drug does not change the con-
temporaneous propensity for populations of a particular country to suffer from cardiovascular disease,
for example. One might think that discovery of an effective innovative product would increase life
expectancy and therefore alter the demographic trends we measure2. However, the fact that we use
demographics over a 4 year period of time contemporaneous to product launch makes this unlikely
and protects us from such reverse causality. It is not likely that a new product could so quickly affect
deaths from the disease.
Thus we expect demographics to be uncorrelated with the error term in our regression of new
drug counts. For our assumption to be violated, it must be the case that a novel therapy generates
additional measurable diagnoses in the specific area. While this makes sense for narrowly targeted
treatments and diagnoses, it seems much less likely to be operating at the level of fairly coarse dis-
ease areas tracked by WHO, such as “cardiovascular disease”. By using this instrumental variables
approach, we can isolate the impact of revenue changes driven by demographics and determine their
2Lichtenberg and Duflos (2008) provides evidence of this channel.
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impact on innovation.
We use international data to reflect the fact that all markets, including those outside the US,
constitute an important incentive for innovation. Additionally, biopharmaceutical research is carried
out all across the globe by both local and international firms. In our view, therefore, the appropriate
level of analysis for a study of the determinants of innovation – both in terms of which products to
include and which markets to count - is global.
We begin in section 2 by reviewing the existing literature that seeks to estimate the elasticity of
innovation with respect to market size. In section 3 we set out a conceptual framework for thinking
about how innovation might be related to market size. Section 4 describes our data. Section 5 gives
our detailed results. Section 6 concludes.
2 Literature Review
There is a substantial and varied literature on the topic of the elasticity of pharmaceutical inno-
vation to expected market size. Some of the variation comes from the measures of innovation used.
Grabowski and Vernon (2000), for instance, use accounting data to estimate the determinants of R&D.
In theory, under perfect capital markets R&D would be chosen only in response to expected future
profitability of the project. However, if capital markets are imperfect and external funds are more
expensive than internal cash flow, current revenue (market size) will have a positive impact on the
amount of research funded by the firm. Of course, if current market size is a proxy for future market
size, then current research may be responding to future sales opportunities also, but these two effects
are difficult to disentangle. In a similar spirit, Giacotto et al. (2005) regress R&D-to-sales ratio on
the pharmaceutical price index from the previous year and other variables. In this setting innovation
may be responding to expected future market size and also the increased revenues the firm earned last
period. This paper estimates that a 1% increase in price leads to a 0.58% increase in R&D spending.
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A variety of other measures of innovation have been used in the literature. One of these measures
is the extent of clinical trials (see Yin, 2008, 2009). Blume-Kohout and Sood (2012), hereafter BKS,
exploit a policy change that creates both a current and future positive shock to market size. They
find a strong response of clinical trials to the policy change, and note in their discussion that the effect
is likely to be a combination of the contemporaneous cash-flow effect and the effect of investing more
heavily in markets that are expected to be more profitable. Kyle and McGahan (2012) measure new
clinical trials (or drug candidates) to estimate the elasticity of new clinical trials to market across
countries and according to the presence of patent protection.
In addition to clinical trials, innovation has been measured by numbers of relevant journal articles
or disease regimens (Lichtenberg, 2006). Similarly, there have been many different measures of poten-
tial market size. For instance, mortality can be measured as (negative) disability-adjusted life years
(DALY) or mortality (Civan and Maloney, 2006,2009, Lichtenberg, 2005). Lichtenberg (2005) finds
a result of similar magnitude to that of Giacotto et al: a 1% increase in the number of people with
cancer leads to a .58% increase in chemotherapy regimens. Civan and Maloney (2006, 2009) find that
a 1% increase in expected US entry price leads to .5% increase in the number of drugs in the drug
development pipeline. Lichtenberg (2005) finds that a 1% increase in DALY leads to a 1.3% increase
in global drug launches.
Acemoglu and Linn (2004), hereafter AL, measure innovation using new drugs launched, as we do,
although they include generic drugs in much of their analysis. AL exploits variation from 1970-2000
in the expenditure share of different US age cohorts for different therapeutic classes. For example,
older people consume more cardiovascular drugs, but the number of older people varies over time.
They combine this with data on all US FDA-approved new products and find that a 1% increase in
contemporaneous expenditure shares leads to a 4% increase in the number of new drugs released on
the market. This is a markedly higher elasticity than found in the remainder of the literature.
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As we do here, AL rely for identification on changes in the variables that exogenously affect mar-
ket size. Some papers in the literature instead estimate directly the impact of policy changes. The
paper by Amy Finkelstein (2004) is an example of this approach focused specifically on the vaccine
market. She exploits two kinds of policy change in the United States. One is when there are changes
in the official recommendations as to who should be vaccinated, as such changes can dramatically
affect market size. A second type of policy change she exploits is the introduction of liability protec-
tion for vaccine makers in the United States. This should have increased the profitability of vaccine
markets and stimulated more investment. Using three policy experiments of this type she finds that
a 1% increase in revenue leads to a 2.75% increase in the number of marketed vaccines. We cannot
directly compare her elasticity to ours because there are significant differences between vaccine and
drug innovation and approval costs.
The study by BKS previously mentioned is also in this tradition. The authors take advantage
of the passage of Medicare Part D, which is a subsidized prescription drug program for elderly and
disabled Americans. The program substantially expanded demand for prescription pharmaceuticals
by this group, as many had been uninsured previously and the program was generously subsidized.
As in Duggan and Scott Morton (2010), they create a variable Medicare Market Share that measures
what fraction of consumers of a particular drug or therapeutic class are eligible for the program. They
then look to see if trials increase for therapeutic areas that have the greatest expansion in demand,
and find that they do. Their elasticity estimate is that a 1% increase in market size yields a 2.8%
increase in early stage clinical trials.
The large variety of measures of both potential market size and innovation are partly responsible
for the wide range of elasticity estimates. It is quite possible, for instance, that clinical trials respond
fairly elastically to potential market size but that the proportion of clinical trials that result in effec-
tive innovation may decline, leading to a less elastic response of effective innovation. Although our
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measures of new drug launches represent a more accurate measure of innovation than do clinical trials
(since the latter are an input rather than an output of the innovative process), we should stress that
even our own measures are far from capturing what really matters for patients, which is welfare.
There are various reasons why it is not straightforward to draw welfare implications from measures
of new drug launches. One is that there may be diminishing marginal health benefits from innovation:
the first radical innovation in a therapeutic class may produce much greater overall benefits than a
drug that is just sufficiently different from it to be granted a patent. A second reason is that it is
particularly difficult in this line of research to calculate the welfare of a new innovation in the absence
of measures of consumers’ valuation or willingness to pay. Most patients are insured and therefore
do not face a marginal price when buying biopharmaceuticals. The buyer in most cases is either the
nation in the case of national health systems, or the large PBMs, in the case of private healthcare
(USA), or some national systems like Germany. This buyer, while not the patient, is the one that
controls the formulary and pays at the margin, and so, from the point of view of the researcher, has
revealed a valuation for the treatment. However, some of these buyers may have monopsony power
and face political constraints, so using negotiated prices may not closely reflect consumer welfare. An
alternative approach to calculating welfare is to simply measure life years saved by the new innovations
and multiply by QALY, though comparable data for many of these products is sparse. Our elastici-
ties should therefore be interpreted only in terms of new product numbers and great care should be
exercised before any welfare conclusions are explicitly or implicitly drawn from them.
3 A Framework for Understanding the Relevance of Market Size for
Innovation
We are interested in the effect of expected market size on innovation. The bulk of the empirical
literature we have surveyed finds an elasticity substantially below one, which implies that innovation
increases with market size, but less than proportionately so. That the relationship should be increas-
ing seems obvious: higher revenues in a market translate into higher profits, which attract additional
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entry from new drugs. But it is not so obvious why entry should be less than proportionate. Many
factors might play a role. One is decreasing margins as competition intensifies. Another is that as
more firms are attracted into a market, there is a greater chance that some of them duplicate each
others’ research efforts.
Relatedly, if there is a limited amount of ”low-hanging fruit” to be plucked, then the more re-
search teams are seeking to enter a market the lower will be the average productivity of each one.
Note that this point remains valid whether firms enter the market sequentially or simultaneously. The
low-hanging fruit need not necessarily be plucked first; all that matters is that if there are fewer com-
petitors each one has a higher probability of finding the low-hanging fruit. Similarly, if the average
costs of clinical trials are increasing with market size (because it is necessary for the developers of a
drug to do more to prove its additional clinical effectiveness) then average productivity may decline,
regardless of whether this is a cross-sectional comparison or a comparison over time.
Apart from AL, the previous empirical literature does not explicitly model the process of pharma-
ceutical competition, nor does it take a stand on the way in which the outcome of R & D competition
might vary systematically in relation to market size. Here we discuss the implications for this rela-
tionship of four main features of the pharmaceutical industry.
First, entry into the market for pharmaceutical profits is endogenous, driven by expected profits.
While this might seem a statement of the obvious, it highlights that the bulk of innovation in this
industry is carried out by for-profit organizations that seek to earn revenue from their inventions.
Secondly, the scale of each research project is a choice variable of the firm - in other words, the fixed
costs of entry into pharmaceutical markets are also endogenous. We can weakly sign the direction of
this relationship, but not its functional form: the larger are the expected profits the larger the scale
of the research projects that are undertaken, and therefore the higher the costs.
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Thirdly, in many pharmaceutical markets there is competition between products that are at least
partial substitutes. There is no ”winner-take-all” process by which the best product captures all or
almost all of the market. In our data, it is typically the case that drugs are somewhat differentiated
in their side effects and efficacy for different groups, and each makes positive sales over time even in
the presence of others in the same class.3
Fourthly, there is evidence that the more products there are available for treatment of a particular
clinical condition, the lower are the margins on each product. This phenomenon has been studied
in the work of Bresnahan and Reiss, most notably, as a common feature of markets with fixed costs
of entry. When margins decline with the number of entrants, each additional entrant requires com-
mensurately more market size. Declining margins in the pharmaceutical industry occur both through
discounting from the list price in the US market, and also via price regulation in other markets such
as those in Europe. In the latter markets, while there is considerable flexibility in the pricing of a
first drug in this therapeutic class, subsequent drugs in each category (”therapeutic competitors”) are
often constrained by some form of reference pricing.
In principle one might model a process of competition that captures these four features in a num-
ber of different ways. To fix ideas, we describe in the Appendix a simple version of the well-known
circle model of horizontal product differentiation due to Salop (1979), extended to incorporate vertical
differentiation in the manner of Armstrong and Weeds (2005). This captures the idea that different
drugs within a certain category may exert some pricing pressure on one another without any one drug
being unambiguously the best in its category and therefore taking all the revenue. This example is
not intended to capture all the important features of pharmaceutical competition, but it captures the
four features above and delivers a clear and intuitive prediction about the magnitude of the market
3The model of Acemoglu and Linn (2004) involves a process of purely vertical differentiation between drugs, implying
that each new drug immediately captures 100% market share which it retains until the next improved drug is launched.
For the reasons we mention, this is inconsistent with substantial evidence of horizontal differentiation in the industry
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size elasticity4. It is therefore a helpful way to understand some of the underlying processes at work.
In this framework, when a firm considers whether it should invest or not, the firm forms expecta-
tions about revenues of the product over its lifetime, taking into account the productivity of the firm’s
own research programs and those of its rivals. We assume that firms have rational expectations of the
number of rivals, shares and prices.
Consider a circle of unit size, with a mass m of consumers uniformly distributed around the circle.
We shall call this parameter m the ”potential demand”, and note that it is not the same as actual
market size (measured by revenue) since the latter will depend on other conditions including prices.
Around this circle N firms are located at equal intervals. Firm i is located at point i/N , and incurs a
fixed cost of investment to produce a drug of quality vi which it sells at price pi; the number of firms
N will be determined by the requirement that the marginal firm makes zero profits (we shall ignore
integer problems). We initially model this fixed cost of investment as a constant exogenous cost K,
then consider what happens when firms can invest to increase the quality of their drugs.
A consumer purchases at most one unit of the drug, and has an outside option yielding utility
normalized to zero, so will purchase uniquely if doing so yields weakly positive utility. The consumer’s
net utility is reduced by a linear transport cost t per unit of distance from the drug purchased. To
simplify the algebra we assume marginal costs of production are zero, and that there is market cover-
age – every consumer buys from at least one firm.5
As we show in the Appendix, the equilibrium value of N is given by the equation
N∗ =
√
mt
2K
4For instance, the model would be unsuited to capture competition when asymmetries are important, such as entry
by a small biotech firm against a vertically integrated pharma giant. That would be a very different problem from the
one considered here
5This is less restrictive than it may appear since for a given potential market size m there will either be no entry or
else, if quality is above some minimal threshold, firms will enter until the available space on the circle is entirely occupied.
13
Then, industry profits are zero and industry revenue is NK.
This yields a monotonic, strictly concave, relationship between potential demand m and the num-
ber of firms N (hence of pharmaceutical products in the market), with N proportional to the square
root of m, and an elasticity of N with respect to m of 0.5. 6
However, potential demand as we have defined it (and which is measured by the parameter m) is
not the same as total revenue NK. m is proportional to the number of firms, and thus the elasticity
of the number of firms with respect to m is one. The reason why the elasticity with respect to revenue
is lower than that with respect to m is simply that revenue does not increase proportionately to m.
Greater potential demand (that is, higher m) attracts more firms and the increased competition lowers
prices, thereby depressing revenue.
Next we relax the assumption that fixed costs of entry are constant and exogenous, but are instead
related to vertical quality. Specifically, costs are K + γ(vi−v)
2
2 for an innovation of quality level vi. An
interior solution to the model requires that the cost γ of improving quality is above a threshold given
by γ > m/2t.
Then, as we show in Appendix 1, the equilibrium number of drugs is given by
N∗ =
√
mt
K
(
1− m
2tγ
)
which implies, not surprisingly, that it increases more slowly in potential demand than when fixed
costs are exogenous. In effect, increases in m induce entry but also raise fixed costs, thereby dampen-
ing the extent of entry in equilibrium beyond the dampening effect that comes from falling margins.
We show that this implies that the equilibrium number of drugs is increasing in total revenue, but less
than proportionately so.
6For comparison, with a quadratic transport cost function t(x) = tx2, as we would obtain N =
(
mt
2K
) 1
3 with a
corresponding elasticity of 1
3
.
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This simple example provides a rationale for expecting that, in our empirical study, the number of
innovations will be increasing in revenue, but less than proportionately. Similarly, to the extent that
the estimated elasticity of the number of drugs with respect to expected total revenue is less than
one, this must be because fixed costs of entry are rising as total market size rises. Whether this is
because fixed costs are rising endogenously as firms invest in vertical product differentiation, or be-
cause the costs of entry for a drug of given quality are themselves rising, the estimation cannot tell us.7
4 Data description
We measure expected market size as the lifetime revenue accruing to the average product that is
launched during a particular time window. Our measure of innovation is a count of new chemical
entities (NCE) by therapeutic category launched anywhere in the 14 countries from which we have
revenue data. While lumpy because of their small numbers, we consider these products to be uncon-
troversially innovative. Drug approval agencies such as the FDA in the US will approve new varieties
and forms of existing medications (e.g. extended release, injectable versus oral) and generic drugs;
these do not fall into our definition of innovative. We limit our measure to products that have actually
been marketed - and therefore survived all the steps in the innovative process from research through
to marketing in order to take advantage of the information contained in those stages.
Our dataset comes from IMS (Intercontinental Marketing Services) Health and includes all product
sales in 14 countries (Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Mexico, Korea,
Spain, Turkey, United Kingdom, USA) between 1997 and 2007 (except for China, where 1997 and
1998 are missing). The data report sales by value and unit volume for all pharmaceutical and biologic
products. All values are deflated into 2007 US$ using the US consumer price index. The database
7This interpretation of innovations as being equivalent to entry by firms in the Salop example implies that each
decision to undertake R&D on a particular drug is independent of the other drugs in a firm’s portfolio (in effect, each
drug is treated as an independent firm). This is clearly not literally true, but complicating the model to introduce it is
beyond the scope of this paper. Moreover, as innovation is to some extent serendipitous, even the firm cannot perfectly
manage portfolio effects.
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reflects sales for all compounds in all 14 countries through retail pharmacies, hospitals and HMOs, and
includes characteristics of drugs like their four-digit Anatomical Therapeutic Classification (ATC4)
(607 different classes are reported), the main active ingredient of the drug (6216 different active in-
gredients are reported), the name of the firm producing the drug, whether it has been licensed, the
patent start date, and the format of the drug (471 different formats are reported). Products in the
same ATC4 by definition have the same indication and mechanism of action. Some other available
and interesting drug characteristics are its brand type - licensed brand, original brand, other brand, or
unbranded - and (when applicable) its patent expiry date - ranging from 1966 to 2030 in the available
data, and which may differ from one country to another. We consider only ethical drugs and not
OTC drugs. Quantities are given in standard units, one standard unit corresponding to the smallest
common dose of a product form, as defined by IMS Health.
Overall, the initial dataset has 6,163,465 observations (one per drug, country, year) but only
2,972,419 have strictly positive revenues and quantities (many observations correspond to years where
the drug was not yet launched, or had disappeared in a given year and country, or to missing data on
revenues or quantities). We keep only the 251,558 observations on branded drugs (i.e. those where
the brand type is either a licensed brand or the original brand) in order to focus on revenues from
patented pharmaceutical innovations. In addition, this restriction leads to dropping many other active
ingredients (4503), formats (217) and ATC4 (217) that appear in generic form only. Finally, since
patents last 20 years, only the 68,219 observations that have their first patent date (throughout the
different countries) after 1977 are kept, in order to have at least one observation (revenue & quantity)
in all countries where the drug was sold. We end up with a data set where 630 active ingredients are
present in 238 ATC4 classes.8 We also categorize drugs into coarser ATC categories.
8As for China, all observations for 1997 and 1998 have been dropped, revenues and quantities are zero at the same time
for all drugs. It is clear that China was not observed these years, for unexplained reasons. After removing observations
with zero revenue or quantity, some active ingredients and ATC4 classes disappear but we still have 6091 different active
ingredients and 606 ATC 4 categories. We dropped data from one country, India, where brand type is always unavailable
in the data (‘patent N/A’). In total, our restrictions to current branded products with complete data leads us to drop
1083 active ingredients, 151 ATC4, 109 formats and 30 patent years.
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In the remaining data set, there are around 900 distinct on-patent products (that is, products
which are on patent at some time during the 11 years of the data). Some of these are essentially the
same product in a different package; our procedure ensures that we treat these as a single product.
All sales and prices are at the manufacturer levels, as reported by IMS, and thus approximate
actual prices, except to the extent of off-invoice discounts. We believe these off-invoice discounts are
not a very large factor in our data. For the US, Danzon and Furukawa (2006) compared the IMS
prices with US average sales price (ASP), which includes all discounts, as reported by the Centers for
Medicare and Medicaid Services (CMS) for the corresponding quarter, and found that on average, the
IMS prices are similar to the ASPs. However, to the extent that unmeasured discounts exist, prices
and revenues may be overestimated here.
We also use demographic data (population and mortality data) from the World Health Organiza-
tion (WHO)9. We extracted population data for the studied countries from available years since 1970.
For all available country-years, we have population by sex (M/F) and by age distribution (0, 1-4, 5-9,
. . . , 70-74, 75+), except for Mexico in 1977, where only total population by sex is available. Missing
population information is reconstructed through a regression in logs on a country specific effect and
a time trend. This amounts to assuming that population evolves between available years of data at a
country specific annual growth rate that changes over time at the same rate across countries.
Mortality data across years and countries are available per disease category as classified using the
ICD-10 classification. Of course, disease categories and drug categories (ATC classes) are different
things but one can attribute to each ATC class a ”most likely” disease category in the ICD 10 classi-
fication. These are summarized in Table 13 in the Appendix.
It is important to realize that the time series dimension of the demographic data contains little
”news”, at least from year to year. Population projections change only slowly over time, as do mor-
9See http://www.who.int/whosis/mort/download/en/index.html.
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tality risks in any given demographic category. For this reason the time periods that constitute an
”observation” in our empirical work are four years long.
The dependent variable is the total number of new chemical entities marketed anywhere in our
14 countries in a given disease category throughout a given time period. Only about one-third of
the drugs approved annually in the United States are new compounds, or chemical entities; the rest
represent modified forms or new uses of existing drugs.
These data in combination allow us to measure how the global size of the market for a drug in a
particular category (for example, cardiovascular) shifts over years according to population and disease
profile, and also allows us to see how many new NCEs (New Chemical Entities) pharmaceutical firms
launch as the market size changes.
5 Estimation Method
5.1 Heuristic description
The first step in estimating the elasticity of innovation is the construction of an expected revenue
measure. We do this by measuring market size over time for various disease categories in our set of
countries. Then we measure how many new products are introduced over time, again by category. We
describe our empirical procedure below.
We exploit differences across brand revenue in different therapeutic categories and different coun-
tries to estimate the potential market for an innovator in those different countries. For example, at
launch the brand will have a share of revenues in the therapeutic category in the country. These
revenues may change over time as the brand goes through its lifecycle, and will begin to decline
when the patent expires and the brand faces significant new competition, or when the entry of substi-
tute drugs causes the brand’s price and/or share to drop. These patterns will vary across jurisdictions.
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Price levels are determined by willingness to pay and the level of competition among products.
A nation’s ability and willingness to pay for healthcare will depend on whether it is nationally or
privately financed and on the preferences of consumers and voters. In general, prices for biopharma-
ceuticals are higher in richer countries compared to poorer ones. Competitive conditions also vary by
country according to the conduct of buyers, and these affect the realized market size available to the
innovator. The different income levels and competitive landscapes across different nations will affect
the price levels observed in the data. In general, prices, market structures, entry, market exclusivity
and other features vary across countries. We will not model these because we can measure the average
outcome, namely revenue per drug, and we assume firms anticipate these market conditions when
making R&D decisions.
Our data allow us in principle to compute the global revenue obtained per innovation as observed
in sales revenue in the data. Since in our actual data set, we observe only 11 years of revenue, we
implement an imputation method to obtain a series of parameters for each ATC class that allows us
to predict revenue for a drug over its entire lifecycle using the average lifecycle within the class. We
then use this estimate as the forecast of manufacturers making innovation decisions.
This process will generate some measurement error that could be expected to lead to a degree of
attenuation bias on the coefficients of an Ordinary Least Squares estimation procedure. Together with
our concerns about possible reverse causality between innovation and revenues, this provides a strong
argument for using an instrumental variables approach. We use as an instrument for total market
revenue in each drug category a measure of potential demand (the equivalent of m in our theoretical
model). We operationalize this idea by using population by age or gender by country, and GDP,
and disease mortality in different countries; prevalence data, which in principle would be stronger
instruments, are unfortunately not available for enough diseases in enough countries. We discuss
the instrument set in greater detail below. However, as will be seen, the instruments we do use prove
to be sufficiently strong for our purposes (that is, sufficiently correlated with the endogenous variable).
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For our instruments to be valid, innovation must not have any direct effect on our measure of
potential market size, which requires that there are no changes in WHO-measured morbidity or mor-
tality that are driven by the innovation in the short run. Indeed, innovation in class c at period t can
affect future longevity and potential market size of later periods (as hypothesized by Cerda, 2007 for
example), but not that of the current and subsequent periods corresponding to the patent life of the
innovation. It seems reasonable to assume that class specific innovations cannot affect population size
in the short run because of competing risks in other disease categories are likely to limit the immediate
effect on mortality of an innovation.
5.2 Formal Definition of Market Size
Let d denote an active ingredient (or chemical entity) in a particular use class, hereafter known as
a drug (all revenues correspond to revenues summed at the level of the chemical entity for different
forms or brands with that chemical entity). We denote by Rtd the revenue obtained for drug d at
year t. Given that the IMS data are converted into current dollars taking already account of each
year’s exchange rate, we measure these revenues by summing all countries’ sales and transform them
into constant US dollars of 2007 using the Consumer Price Index for inflation. Our average drug has
positive revenues for about twenty years (while the patent only last for 20 years, the brand is not
typically launched until years after filing, and brands typically earn profits after patent expiration in
many markets.) This leads us to write the total revenue obtained thanks to the patent for drug d as
R˜d =
∑t0+20
t=t0
δt
−t0Rtd
where δ is the discount factor. We assume that these discounted revenues per drug determine invest-
ment decisions of firms.
We denote by C = {1, .., C} a partition of the set of therapeutic classes (the 1 digit ATC classes).
For a sub-set of drugs in set c ∈ C that are launched in year t, we denote by W tc the sum of global
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revenues obtained in this segment c by all innovations of period t :
W tc =
∑
{d∈c,t0=t} R˜d
We will call this the “period t innovation - class c” market size.
Then, we denote by N tc the number of new chemical entities (active ingredients) patented at t in
class c. There is no revenue W tc (W
t
c = 0) when no drug was patented that year in that category.
As our model shows, we expect a positive relationship between market size and innovation. In the
empirics this shows up as the relationship between the number of new chemical entities per class in
period t (N tc) and the period t innovation size of class c (W
t
c ).
The arrival of new products on the market is stochastic due to uncertainties in the research process
and in regulatory approval. Our measure of innovation in a single year will be lumpy from year to year
and contains zeros. However, as discussed above, because there is little new news in demographics
every year, we use periods of 4 years for t, a procedure which smooths out our innovation measure N tc .
5.3 Imputation of Revenues over Drug Life-cycles
Because we observe only 11 years of data, we implement an imputation method to obtain a series of
parameters for each ATC class that allows us to predict revenue for a drug over its entire lifecycle
using the average lifecycle within the class. We then use this estimate as the manufacturer’s forecast
of market size that it uses as its input into innovation decisions.
For a given drug d, the data do not allow us to observe all the Rtd for years t
0, t0 + 1, ..., t0 + 19.
As we want to take into account the lifecycle of drugs, we compute the average evolution of revenues
of new chemical entities within a class c between patent age τ and τ + 1 as the ratio between patent
age τ and τ + 1 of average revenue (across active ingredients) for all drugs of a given drug category c.
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Defining Γ(c) as the set of drugs in class c, we can also use the following definition 10:
λτc =
1
#Γ(c)
∑
d∈Γ(c)
Rt
0+τ+1
d
Rt
0+τ
d
Assuming that the expected revenue of a drug of class c will follow the life-cycle pattern estimated
using these λτc we can estimate the revenue at a given future patent year. Then, when R
τ+1
d is not ob-
served, we estimate it with Rt
0+τ+1
d = λ
τ
c(d)R
t0+τ
d which allows us to reconstruct the lifecycle revenues
of any drug on the market during the period of our data.
6 Empirical Results
We will consider two levels of ATC classes C and C′. The finer level of classification (2 digit ATC
classes) considered will be C′. A class denoted c′ will thus correspond to an element of this finer
classification. With the previous notations, W
t
c
Ntc
is the lifecycle revenue per new chemical entity in
class c and ”born” during patent period t. All revenues are expressed in thousands of 2007 US dollars
and the discount factor used is δ = 0.95.
6.1 Descriptive Statistics
Table 1 presents descriptive statistics by ATC class on the number of innovations and lifecycle rev-
enues per ATC class at level 1. Table 2 shows the same statistics as Table 1 but using the 2 digit
ATC classification. Figure 1 presents the same data as Table 1, but averaged not over ATC class but
according to the number of new chemical entities. This shows a broad descriptive relationship between
market size and the number of new chemical entities. On average, the total revenue per ATC class
seems to be broadly increasing with the number of innovations except when the number of innovations
is the largest. This result holds on aggregate and does not account for the heterogeneity of revenues
and innovations across categories of ATC classes.
10Using a definition of λτc that gives weights to active ingredients proportional to their revenue in the class, we have
λτc =
∑
d∈Γ(c) R
t0+τ+1
d∑
d∈Γ(c) R
t0+τ
d
, which leads to similar results.
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6.2 Lifecycle of drugs
Our imputed lifecycle revenues are shown in Figure 2 for all categories (digit 1 ATC classes) and
patent ages. Figure 2 shows the mean revenues of drugs by class for each patent age and ATC-1. For
these shapes to be easily compared on one page, we have normalized the total sales for patent year 10
for all drug classes, which implies that the height of each vertical bar should not be compared across
drug categories.
We can see that the lifecycle of sales of drugs is not uniform across classes. Some classes have longer
delays of penetration, some classes have lower duration. It seems important to take into account the
expected lifecycle of the patent revenues of drugs in the incentives to innovate for the pharmaceutical
industry.
6.3 Elasticity of Innovation to Market Size
We now look at the relationship between the number of innovations or New Chemical Entities N tc at
period t in category c and our ”market size” W tc . In each year we have data from 238 therapeutic
classes. As noted above, we sum revenue and innovation in four year periods (which reduces the
sample size but creates much more content to each observation). Our time periods t are thus 1977-80,
1981-84, 1985-88, 1989-92, 1993-96, 1997-2000, 2001-04, 2005-2007.
We use several specifications to estimate the elasticity of innovation with respect to market size.
First, we estimate the following model
lnN tc = α lnW
t
c + γc + δt + ε
t
c
which relates the number of innovations (number of NCEs) patented in period t in each class to the
total revenue provided by sales of all drugs (on patent and licensed) in the class during the duration
of the patents issued at t.
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In this reduced form model, α can be interpreted as the elasticity of innovation to market size, γc
is a fixed unobserved effect specific to the ATC class c, δt is a common unobserved period effect and
εtc an unobserved random shock on the innovation outcome.
Assuming all right hand side variables are exogenous means that
E
(
εtc| lnW tc , γc, δt
)
= 0
We first estimate such a model using OLS. Then we employ 2SLS, both because of the likelihood
of measurement error in the construction of the revenue measures, and to deal with the possibility
of reverse causality between innovation and market size. Our instrumental variables are demographic
and economic: population and mortality by disease in different countries, and GDP. To be valid in-
struments, demographics and disease mortality must be correlated with market size, and as we shall
see the instruments easily pass F-tests in the first stage of the estimation. Secondly, innovation, or
launch of new products, must not directly cause changes in demographics or disease mortality. We
can imagine that at a very fine level of categorization, this could be a problem. For example, a pill
for Asperger’s syndrome (mild autism) might well increase diagnoses of Asperger’s and therefore the
recorded incidence of autism. But the WHO data we use are much coarser: for example, how many
people died of cardiovascular diseases in period t. We do not think the therapies available for different
cardiovascular diseases affect this measurement.
For this reason, we use male, female, and ”more than 50 years old” population variables, as well as
GDP, and the number of deaths of males and females for the disease categories that each drug class
(ATC class) can be considered to target. These instruments vary across periods and drug classes.
They are interacted with dummy variables for 1-digit ATC classes or 2 digit ATC classes depending
on the case.
24
For the population measures we compute the size of the population in countries where drugs of
each ATC class are sold and sum this over countries and years for the duration of the patent. This
population is denoted P ct . This instrument varies not only over time but also across ATC classes. We
use a similar definition for male or female population, and for the ”over 50 years old” population.
Table 3 details the different sets of instruments used in the regressions below. As will be seen, these
sets of instruments satisfy the different usual tests of exclusion (Sargan test of overidentifying restric-
tions) and of significance in the first stage (F test of joint significance of excluded IVs in the first stage
regression). In our empirical work, set A will be used for regressions at the ATC-1 level and B, C or
D for regressions at the ATC-2 level.
Recall that the number of innovations N tc that can be observed on each market is censored at zero,
and that W tc is unobserved when there are zero innovations. We have a fundamental problem of un-
observed potential market size of any innovation that did not happen and therefore need a truncated
regression model. In particular, it could be that εtc is not mean independent of all right-hand-side
variables because of the truncation of the model when N tc = 0.
With some parametric assumptions on εtc, one can estimate the model taking into account the
truncation11. For example, as we are dealing with count data, we can assume a Poisson distribution
for the number of innovations, such that
P
(
N tc = n
)
=
exp (−µ)µn
n!
where we specify the intensity parameter µ as µ = exp
[
αW tc + βc + δt
]
. Such a model implies that
E
(
N tc |W tc , βc, δt
)
= exp
[
αW tc + βc + δt
]
11Nonparametric estimation of such a truncated regression model is difficult and is a subject of ongoing research (Lewbel
and Linton, 2002, Chen 2009). Chen (2009) and Lewbel and Linton (2002) show that if the exogeneity assumption of right
hand side variables is satisfied, then with some additional technical assumptions, one can identify the non parametric
conditional expectation of the truncated dependent variable conditionally on the right hand side variables.
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As the data are truncated at zero sinceW tc is unobserved whenN
t
c = 0, we correct for the truncation
using the zero-truncated Poisson maximum-likelihood regression implying that
P
(
N tc = n|N tc > 0
)
=
exp (−µ)µn
n! (1− exp (−µ))
with
µ = exp
[
αW tc + βc + δt
]
In this case, we take into account the endogeneity of W tc using a control function approach. As sug-
gested by Wooldridge (2002) and Blundell and Powell (2003), this technique is useful for non linear
models. It amounts to performing a first stage regression of the endogenous variables on all exogenous
variables and excluded instruments and then using residuals and polynomials of these residuals as
additional ”control” variables in the main regression (here the zero-truncated Poisson). The results
of these first stage regressions are shown in Appendix 2. They show that the excluded instruments
are highly statistically significant (as confirmed also by the joint F test shown at the bottom of the
Tables). In the case of the control function approaches, we used sets of instruments A for analysis of
N tc and D for N
t
c′ but results are similar with other sets of instruments. In the case of ATC-1 level
regressions, instrumental variables A proved satisfactory and consist in male and female population
of corresponding countries, male and female deaths of corresponding ATC-1 class and countries. In
the case of ATC-2 level regressions, instrumental variables B, C or D proved satisfactory and consist
different male or female demographic variables interacted with ATC-1 or ATC-2 dummies.
In all tables reported here, standard errors are clustered at the class level and shown in parenthe-
ses. Although dummy variables δt for time periods are not shown to conserve space, they are always
significant. Tables 4 and 5 show the results of estimating the linear model for the 1-digit and 2-digit
ATC categories respectively. Tables 6 and 7 show the corresponding results of the estimation of the
count models. In each case we show results with and without instrumenting for potential market size.
All standard errors are clustered at the ATC-1 level.
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The specifications yield a range of elasticities between 3% and 32%, meaning that increasing mar-
ket size by 1% yields an increase in the number of new products of 0.03 to 0.32%. There is no clear
relationship between the elasticity and the type of specification (linear versus count, one-stage versus
two-stage) or the instrument set. Overall, our preferred specification among these is Equation (12).
It takes into account the truncated nature of the data and the need to use instrumental variables,
and it uses the finer set of instruments in which the demographic variables are interacted with 2-digit
therapeutic categories, thus taking account of the fact that different demographic profiles generate
different market sizes in the various treatment categories. It uses the finer 2-digit disease classification
for the dependent variable, which we prefer because we understand it is relatively rare for drugs in
one ATC-2 category to be discovered while searching for therapies in a different ATC-2 category.
Equation (12) yields an elasticity of 10.4%, with a t-ratio of around 7, which gives the elasticity a
confidence interval of around 7.5% to 14.5%12.
However, for this very reason the assumption that the elasticity is the same across disease categories
may not be realistic, since the extent to which the industry has had low-hanging fruit may well vary
for scientific reasons from one disease category to another. To investigate this possibility we estimate
the count model with ATC specific market size coefficients αc using
P
(
N tc = n|N tc > 0
)
=
exp (−µ)µn
n! (1− exp (−µ))
with
µ = exp
[
αcW
t
c + βc + δt
]
which also implies that the elasticity to market size of the expected number of innovations is ∂ lnEN
t
c
∂ lnW tc
=
αcW
t
c .
Given the size of the elasticity, we can also compute how much additional revenue in a given drug
category is needed to obtain one additional innovation as the inverse of the elasticity times the average
12This point estimate enables us easily to reject the hypothesis of an elasticity equal to 1.
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revenue per innovation observed on the market (because dWc =
(
∂ lnNc
∂ lnWc
)−1
Wc
Nc
).
Table 8 reports the estimated elasticities by ATC class. We find higher elasticities on average
than in the model with the elasticity constrained to be constant across disease categories, though they
remain within the range of elasticities found under previous specifications. The average across all
categories is an elasticity of 23.1%.
We see that the elasticities of innovation vary by ATC class, and that the average lifecycle dis-
counted market size increase needed on average to obtain one additional NCE also varies across classes.
For comparison, we estimate the log-linear model with ATC-1 specific elasticities (results not reported),
and find larger absolute values than in a specification without heterogeneity. The values are a lit-
tle smaller than those of this count model, varying between 8% and 30% depending on the disease class.
7 Overall Results and Conclusions
Across all ATC classes, we find that the average elasticity of innovation to market size under this
specification is 23.1%, which implies that the average lifecycle discounted market size increase needed
to obtain one additional NCE is a little under $2.5 billion. Remember that we used a discount factor
of 0.95 which implies that the $2.5 billion over the lifecycle of a drug is equivalent to a constant annual
revenue of $203 million per year over 20 years.
Next we consider whether this estimated $2.5 billion is reasonable. The most recent DiMasi et
al. study of drug development estimates that a new drug incurs approximately $800 million in devel-
opment costs (Adams, 2006, Di Masi et al. 2003 suggest 1$billion on average for one new chemical
entity). Included in this calculation is the cost of capital, the cost of failed drugs, and the cost of
clinical trials, so it is close to the total fixed economic cost of innovation. On top of this there will
be variable costs of production, distribution and marketing. Industry sources have suggested to us
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that 50% of revenue is a reasonable guess at the size of these costs. This suggests that a new drug
would need to cover costs of around $1.6 - $2 billion in order to yield a return to the innovator. This
is a little lower than our estimated market size increase of $2.5 billion needed to induce an additional
innovation. Our elasticity estimate therefore seems broadly plausible in the light of what is known
from accounting data.
Comparing our elasticities to others in the literature is difficult, if only because the dependent
variable changes across research designs from new drugs, to new cancer regimens, to new clinical tri-
als, to journal articles.13
This paper has used new data and methods to quantify the relationship between market size and
innovation in the pharmaceutical industry. We have estimated the elasticity of innovation (as mea-
sured by the number of new chemical entities appearing on the market for a given disease class) to the
expected market size, which is predictable by the potential demand as represented by the willingness
of sufferers from diseases in a class (and others acting on their behalf such as insurers or governments)
to spend on their treatment. We have found significant positive elasticities with a point estimate
under our preferred specification of 23.1%. This suggests that at the mean market size an additional
$2.5 billion is required in additional revenue to induce the invention of one additional new chemical
entity, which appears a reasonable order of magnitude since estimates of the true economic cost of
developing a new chemical entity are around $800 million to $1 billion, and marketing and related
costs represent some 50% of revenue. An elasticity substantially below one is also plausible in the
light of other evidence that innovation in pharmaceuticals is becoming more difficult and expensive
over time, and is compatible both with the hypothesis that the costs of regulatory approval are rising
and the hypothesis that the industry is running out of ”low hanging fruit.”
13However, both we and Acemoglu and Linn (2004) use new product launch as a measure of innovation. Recall that AL
estimate an elasticity of 4: for each 1% increase in revenue, the number of new products increases by 4%, which is over
an order of magnitude larger than our estimate (and of most others in the literature). There are significant empirical
differences that underlie these two different results. Though it is hard to know the impact of these methodological
differences, an elasticity as large as 4 appears to imply that marginal costs of innovation are falling as more innovation
takes place, which does not seem a plausible description of the pharmaceutical industry in the early 21st century.
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Our results are robust to a number of specification choices. However, the availability of data for
more years would undoubtedly help to refine our estimates and we leave this as a subject for future
research.
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8 Tables
Table 1: Total lifetime revenues per 1-digit ATC class of NCEs patented by period,
number of entities per period, and revenue per entity. Unweighted averages by 1-digit
ATC class
Mean
ATC class (C) Revenue Revenue/NCE NCEs
A: ALIMENTARY TRACT AND METABOLISM 1,997,826 163,843 11.14
B: BLOOD AND BLOOD FORMING ORGANS 3,701,079 500,325 6.67
C: CARDIOVASCULAR SYSTEM 3,308,513 244,189 15.40
D: DERMATOLOGICALS 154,469 26,107 5.00
G: GENITO URINARY SYSTEM AND SEX HORMONES 766,708 186,582 5.33
H: SYSTEMIC HORM.PREP., EXCL. SEX&INSULINS 12,367 5,819 2.20
J: ANTIINFECTIVES FOR SYSTEMIC USE 5,143,563 287,484 14.86
L: ANTINEOPLASTIC&IMMUNOMODULATING AGENTS 6,186,700 356,245 12.29
M: MUSCULO-SKELETAL SYSTEM 2,533,836 435,531 6.17
N: NERVOUS SYSTEM 922,092 110,062 8.86
P: ANTIPARASITICS INSECTICIDES REPELLENTS 9,099 4,550 1.50
R: RESPIRATORY SYSTEM 817,279 106,635 7.40
S: SENSORY ORGANS 176,610 51,700 4.40
All 2,219,998 207,642 8.36
Table 2: Total lifetime revenues per 2-digit ATC class of NCEs patented by period,
number of entities per year, and revenue per entity. Unweighted averages by 1-digit
ATC class
Mean
ATC class (C) Revenue Revenue/NCE NCEs
A: ALIMENTARY TRACT AND METABOLISM 388,466 102,302 2.19
B: BLOOD AND BLOOD FORMING ORGANS 2,018,771 829,847 3.64
C: CARDIOVASCULAR SYSTEM 612,688 195,832 3.04
D: DERMATOLOGICALS 51,490 27,669 1.72
G: GENITO URINARY SYSTEM AND SEX HORMONES 328,589 110,256 2.29
H: SYSTEMIC HORM.PREP., EXCL. SEX&INSULINS 7,729 6,932 1.38
J: ANTIINFECTIVES FOR SYSTEMIC USE 1,894,997 426,064 5.47
L: ANTINEOPLASTIC&IMMUNOMODULATING AGENTS 1,968,495 368,423 3.91
M: MUSCULO-SKELETAL SYSTEM 844,612 265,419 2.11
N: NERVOUS SYSTEM 208,214 91,404 2.06
P: ANTIPARASITICS INSECTICIDES REPELLENTS 9,099 4,550 1.50
R: RESPIRATORY SYSTEM 240,376 63,376 2.53
S: SENSORY ORGANS 109,730 32,727 3.13
All 711,146 196,345 2.76
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Table 3: Definition of Instrument Sets
Set Instruments
A · GDP per capita of corresponding countries
· Male and Female Population of corresponding countries
· Male and Female Deaths of corresponding ATC-1 class and countries
B · GDP per capita of corresponding countries
· Population aged 50 and over of corresponding countries, interacted with ATC-1
C · GDP per capita of corresponding countries
· Male Population aged 50 and over of corresponding countries, interacted with ATC-1
D · GDP per capita of corresponding countries
· Male Population aged 50 and over of corresponding countries, interacted with ATC-2
· Female Population aged 50 and over of corresponding countries, interacted with ATC-2
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Table 4: Determinants of the number of New Chemical Entities per therapeutic class
Linear model, 1-digit ATC categories
Linear Model (1) (2)
OLS 2SLS
VARIABLES
Log Total Revenue 0.216*** 0.289***
(0.0289) (0.0428)
ALIMENTARY TRACT AND METABOLISM 0.291*** 0.150*
(0.0572) (0.0834)
ANTIINFECTIVES FOR SYSTEMIC USE 0.549*** 0.322**
(0.0903) (0.133)
ANTINEOPLASTIC IMMUNOMODULATING 0.527*** 0.369***
(0.0888) (0.129)
ANTIPARASITICS -0.133 0.274
(0.170) (0.257)
BLOOD AND BLOOD FORMING ORGANS 0.325*** 0.348***
(0.0314) (0.0383)
CARDIOVASCULAR SYSTEM 0.681*** 0.469***
(0.112) (0.154)
DERMATOLOGICALS 0.245*** 0.329***
(0.0411) (0.0427)
GENITO URINARY SEX HORMONES -0.128* -0.221**
(0.0659) (0.0907)
MUSCULO SKELETAL SYSTEM 0.166** 0.0585
(0.0674) (0.0891)
NERVOUS SYSTEM 0.192** 0.0761
(0.0788) (0.112)
RESPIRATORY SYSTEM 0.407*** 0.367***
(0.0525) (0.0656)
SYSTEMIC HORM 0.248** 0.561***
(0.107) (0.145)
Observations 74 74
R-squared 0.832 0.801
Instruments A
Note: All standard errors are clustered at the ATC-1 level.
*** means significance at 1% level, ** at 5 % level and * at 10% level. Year dummies included are not shown.
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Table 5: Determinants of the number of NCEs per therapeutic class Linear model,
2-digit ATC categories
Linear Model (3) (4) (5) (6)
OLS 2SLS 2SLS 2SLS
VARIABLES
Log Revenue 0.0962*** 0.0875*** 0.0883*** 0.114***
(0.0106) (0.0125) (0.0124) (0.0164)
ALIMENTARY TRACT AND METABOLISM -0.577*** -0.208*** -0.207*** -0.191***
(0.124) (0.0201) (0.0201) (0.0214)
ANTIINFECTIVES FOR SYSTEMIC USE -0.162 0.250*** 0.248*** 0.175***
(0.147) (0.0426) (0.0420) (0.0470)
ANTINEOPLASTIC IMMUNOMODULATING -0.245 0.148*** 0.147*** 0.103***
(0.140) (0.0311) (0.0308) (0.0322)
ANTIPARASITICS -0.685*** -0.349*** -0.347*** -0.276***
(0.145) (0.0372) (0.0369) (0.0488)
BLOOD AND BLOOD FORMING ORGANS -0.352** 0.0375 0.0365 0.00354
(0.141) (0.0355) (0.0355) (0.0392)
CARDIOVASCULAR SYSTEM -0.347** 0.0304 0.0302 0.0224
(0.147) (0.0256) (0.0257) (0.0309)
DERMATOLOGICALS -0.698*** -0.339*** -0.338*** -0.305***
(0.119) (0.0360) (0.0359) (0.0387)
GENITO URINARY SEX HORMONES -0.493*** -0.129*** -0.128*** -0.109***
(0.132) (0.0305) (0.0305) (0.0325)
MUSCULO SKELETAL SYSTEM -0.567*** -0.196*** -0.196*** -0.171***
(0.121) (0.0313) (0.0313) (0.0333)
NERVOUS SYSTEM -0.654*** -0.284*** -0.283*** -0.270***
(0.122) (0.0297) (0.0297) (0.0302)
RESPIRATORY SYSTEM -0.356** 0.00421 0.00524 0.0394
(0.128) (0.0227) (0.0226) (0.0262)
SYSTEMIC HORM -0.559*** -0.204*** -0.202*** -0.119
(0.0809) (0.0772) (0.0772) (0.0891)
Observations 231 231 231 231
R-squared 0.715 0.458 0.459 0.465
Instruments B C D
Note: All standard errors are clustered at the ATC-1 level.
*** means significance at 1% level, ** at 5 % level and * at 10% level. Year dummies included are not shown.
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Table 6: Determinants of the number of NCEs per therapeutic class Count model,
1-digit ATC categories
Count Models (7) (8) (9)
VARIABLES
Log Revenue 4.63e-08* 1.42e-07*** 1.14e-07***
(2.39e-08) (5.27e-08) (2.77e-08)
Corresponding Elasticity 0.103 0.315 0.252
ALIMENTARY TRACT AND METABOLISM 1.798*** 0.737** 1.717***
(0.101) (0.296) (0.155)
ANTIINFECTIVES FOR SYSTEMIC USE 2.000*** 0.523* 1.800***
(0.128) (0.300) (0.218)
ANTINEOPLASTIC IMMUNOMODULATING 1.725*** 0.480 1.285***
(0.221) (0.311) (0.382)
ANTIPARASITICS -0.353*** -1.092*** -0.879***
(0.136) (0.396) (0.132)
BLOOD AND BLOOD FORMING ORGANS 1.195*** 0.386 1.482***
(0.153) (0.312) (0.194)
CARDIOVASCULAR SYSTEM 2.051*** 1.047*** 2.010***
(0.115) (0.272) (0.187)
DERMATOLOGICALS 1.165*** 0.236 1.103***
(0.107) (0.251) (0.126)
GENITO URINARY SEX HORMONES 1.086*** 0.0905 1.047***
(0.111) (0.186) (0.142)
MUSCULO SKELETAL SYSTEM 1.274*** 0.226 1.110***
(0.0871) (0.268) (0.157)
NERVOUS SYSTEM 1.723*** 0.694** 1.566***
(0.114) (0.291) (0.154)
RESPIRATORY SYSTEM 1.459*** 0.477** 1.485***
(0.0978) (0.212) (0.122)
SYSTEMIC HORM 0.282** -0.502** 0.104
(0.121) (0.206) (0.120)
Observations 74 74 74
Method Poisson IV-Poisson Trunc-Poisson
Instruments A A
Control Function (IVs) Yes
Note: All standard errors are clustered at the ATC-1 level.
*** means significance at 1% level, ** at 5 % level and * at 10% level. Year dummies included are not shown.
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Table 7: Determinants of the number of NCEs per therapeutic class Count model,
2-digit ATC categories
Count Models (10) (11) (12)
VARIABLES
Log revenue 8.85e-08*** 4.28e-08 1.47e-07***
(1.87e-08) (4.35e-08) (2.20e-08)
Corresponding Elasticity 0.0630 0.0305 0.104
ALIMENTARY TRACT AND METABOLISM 0.382*** 0.0779 0.0211
(0.125) (0.111) (0.165)
ANTIINFECTIVES FOR SYSTEMIC USE 1.314*** 1.329*** 1.068***
(0.0998) (0.111) (0.119)
ANTINEOPLASTIC IMMUNOMODULATING 0.861*** 1.019*** 0.698***
(0.151) (0.0955) (0.135)
ANTIPARASITICS -0.0607 -0.780*** -0.849***
(0.184) (0.129) (0.226)
BLOOD AND BLOOD FORMING ORGANS 0.774*** 0.755*** 0.531***
(0.156) (0.235) (0.131)
CARDIOVASCULAR SYSTEM 0.683*** 0.484*** 0.401**
(0.139) (0.119) (0.183)
DERMATOLOGICALS 0.191 -0.300*** -0.330*
(0.121) (0.0962) (0.172)
GENITO URINARY SEX HORMONES 0.411*** 0.133 0.0745
(0.138) (0.113) (0.192)
MUSCULO SKELETAL SYSTEM 0.390*** 0.133 -0.0123
(0.109) (0.0930) (0.146)
NERVOUS SYSTEM 0.399*** 0.0777 0.0254
(0.113) (0.0932) (0.165)
RESPIRATORY SYSTEM 0.510*** 0.260** 0.208
(0.140) (0.118) (0.187)
SYSTEMIC HORM 0.188*** -0.562*** -0.603***
(0.0730) (0.0864) (0.117)
Observations 231 231 231
Method Poisson Trunc-Poisson Trunc-Poisson
Instruments A D
Control Function (IVs) Yes Yes
Note: All standard errors are clustered at the ATC-1 level.
*** means significance at 1% level, ** at 5 % level and * at 10% level. Year dummies included are not shown.
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Table 8: Elasticties and Market Size Generating One Innovation per class
Mean Mean
ATC class (C) Elasticity Market Size
Per Innovation
A: ALIMENTARY TRACT AND METABOLISM 0.155 1,729,303
B: BLOOD AND BLOOD FORMING ORGANS 0.069 15,637,100
C: CARDIOVASCULAR SYSTEM 0.098 3,134,607
D: DERMATOLOGICALS 0.245 160,228
G: GENITO URINARY SYSTEM AND SEX HORMONES 0.269 726,358
J: ANTIINFECTIVES FOR SYSTEMIC USE 0.281 3,033,395
L: ANTINEOPLASTIC&IMMUNOMODULATING AGENTS 0.377 2,313,080
M: MUSCULO-SKELETAL SYSTEM 0.151 3,950,014
N: NERVOUS SYSTEM 0.398 386,187
R: RESPIRATORY SYSTEM 0.109 1,258,170
S: SENSORY ORGANS 0.406 148,508
All 0.231 2,471,139
Table 9: International Classification of Diseases and ATC drug categories
ATC Class ICD10 Disease Title
Chapter Blocks
A14, A16 IV E00-E90 Endocrine, nutritional and metabolic diseases
Other A XI K00-K93 Diseases of the digestive system
B III D50-D89 Diseases of the blood and blood-forming organs
and certain disorders involving the immune mechanism
C IX I00-I99 Diseases of the circulatory system
D XII L00-L99 Diseases of the skin and subcutaneous tissue
G XIV N00-N99 Diseases of the genitourinary system
H IV E00-E90 Endocrine, nutritional and metabolic diseases
J I A00-B99 Certain infectious and parasitic diseases
L II C00-D48 Neoplasms
M XIII M00-M99 Diseases of musculoskeletal system and connective tissue
N1,N2,N3 VI G00-G99 Diseases of the nervous system
N4,N5,N6,N7 V F00-F99 Mental and behavioral disorders
P I A00-B99 Certain infectious and parasitic diseases
R X J00-J99 Diseases of the respiratory system
S1 VII H00-H59 Diseases of the eye and adnexa
S2 VIII H60-H95 Diseases of the ear and mastoid process
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9 Appendix 1: Equilibrium Values of N
To find consumer demand in the model of Section 2, note that a consumer located at point c between
firm i and firm i+ 1 and who is indifferent between the two will derive utility Uc where
Uc = vi − pi − t
(
c− i
N
)
= vi+1 − pi+1 − t
(
i+ 1
N
− c
)
from which we can define c, the location of the indifferent consumer under market coverage, as
c =
i
N
+
1
2N
+
vi − vi+1 − (pi − pi+1)
2t
In a symmetric equilibrium in which all firms’ prices and qualities are identical, this means that the
utility of the marginal consumer becomes
Uc = vi − pi − t
2N
(1)
Now, consider what happens if market coverage does not obtain. Then the indifferent consumer is
defined by
vi − pi − t
(
c′ − i
N
)
= 0
where c′ is the marginal consumer in the absence of market coverage. This implies that
c′ =
i
N
+
(vi − pi)
t
Now consider the objective function Πi of firm i. When the quality of products is exogenous and
market coverage is complete, profits of firm i are:
Πi = mpi
(
1
N
+
2vi − vi−1 − vi+1 −
(
2pi − pi−1−pi+1
)
2t
)
−K
Taking first order conditions with respect to prices while qualities are fixed yields:
∂Πi
∂pi
= m
(
1
N
+
2vi − (vi−1 + vi+1) +
(
pi−1+pi+1
)
2t
− 2pi
t
)
= 0
pi =
2t
N
+
(
pi−1+pi+1
)
+ 2vi − (vi−1 + vi+1)
In a symmetric equilibrium where qualities and prices are identical among firms, this implies that
pi =
t
2N
(2)
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We can now use the zero-profit condition to solve for the equilibrium value of N (ignoring integer
problems). Substituting for equilibrium prices in the profit function yields
Πi =
mt
2N2
−K
which when profits are zero implies
N =
√
mt
2K
(3)
Then, industry profits are zero and industry revenue is NK.
This yields a monotonic, strictly concave, relationship between potential demandm and the number
of firms N (hence of pharmaceutical products in the market), with N proportional to the square root
of m. From this we can derive
∂N
∂m
=
1
2
√
t
2mK
=
N
2m
(4)
which implies that the elasticity of N with respect to m is 0.5.
To verify the conditions under which this is consistent with market coverage, note that substituting
(2) into (1) implies that the indifferent consumer c has utility level
Uc = vi − t
N
which for market coverage with exogenous quality implies, by substitution of (3), that
vi ≥
√
2tK
m
So we can conclude that, if quality is exogenous and above some threshold (
√
2tK
m ) that is increasing
in the extent of product differentiation (t) and in fixed entry costs (K), and decreasing in potential
demand (m), then the number of drugs in the market increases as the square root of potential demand.
To conclude the analysis of the case with exogenous quality, we note that if the market were not
fully covered, prices would be given by the expression
pi =
vi
2
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Then, the profit function becomes
Πi =
mvi
2
4
= K
which implies that fixed costs of entry are either too high so that no entry occurs, or low enough so that
entry occurs until it exhausts all available opportunities. For constant fixed cost, this suggests that
market coverage is the only interesting case to study. For fixed costs that vary by potential demand,
entry will be determined entirely by the shape of the cost function: any increase in m will simply raise
the profit threshold for entry, and all firms with fixed costs below the new higher threshold will enter.
In studying endogenous quality, we therefore look only at the case of full market coverage. Then,
the profit function can be written as follows:
Πi = mpi
(
1
N
+
2vi − vi−1 − vi+1 −
(
2pi − pi−1−pi+1
)
2t
)
−
(
K +
γ(vi − v)2
2
)
where K + γ(vi−v)
2
2 is the cost of innovating with an innovation of quality level vi.
This differs from the profit function when quality is exogenous only in that the fixed cost contains
an element that is quadratic in the cost of increasing quality above a certain base level v.
Assume that firms first choose product quality as part of their R&D decisions, then choose prices
once qualities are fixed. When choosing their R&D decisions they take the R&D decisions of other
firms as fixed and therefore also their entry decisions, so N is taken as given by firms choosing quality.
In solving for prices we can no longer presume equilibrium is symmetric. We assume nevertheless
that equilibrium is symmetric among firms other than firm i. Writing pj = pi+1 = pi−1 and analogously
for qualities, taking first order conditions with respect to pi and substituting in the analogous first
order conditions for pj yields
pi =
t
N
+
2 (vi − vj)
3
Substituting for prices in the objective function yields
Πi = m
(
t
N
+
(vi − vj)
3
)(
1
N
+
vi − vj
3t
)
−
(
K +
γ(vi − v)2
2
)
and taking first order conditions with respect to vi yields
m
N
+
4m (vi − vj)
9t
+ γv − γvi = 0
44
which, since equilibrium is symmetric, implies that
vi = v +
m
γN
This incidentally implies that the condition for market coverage can be written as
v +
m
γN
− t
N
− t
2N
≥ 0
which implies a threshold condition for v, namely that v ≥ 3tγ−2m2γN .
We can now use the zero-profit condition to solve for the equilibrium value of N , denoted N∗.
Substituting for equilibrium qualities and prices in the profit function yields
Πi =
mt
N2
−
(
K +
m2
2γN2
)
which when profits are zero implies
N∗ =
√
mt
K
(
1− m
2tγ
)
A real solution for N∗ requires that γ ≥ m2t , which will hold so long as the cost of improving the
product is sufficiently great.
Then, we also have the equilibrium quality of products which is
vi = v +
1
γ
√
mK
t− m2γ
which is increasing in K, decreasing in γ, t.
We can then differentiate N∗ with respect to m to yield:
∂N
∂m
=
t− mγ
2
√
mtK
(
1− m2tγ
)
which is strictly positive so long as γ > m/2t.
With endogenous quality, we no longer find a unit elasticity of the number of firms (or drugs) N∗
with respect to total revenue. In this case, total market revenue R∗ is endogenous and given as a
function of endogenous N∗ by
R∗ (N∗,m) =
(
K +
m2
2γN∗2
)
N∗ = KN∗ +
m2
2γN∗
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which is a U shaped function of N∗ with a minimum at m√
2γK
. It is useful to note that as γ → ∞ it
converges to the expression for revenue under exogenous fixed costs.
However, since for a real solution for N it is necessary that γ ≥ m2t , R∗ (N∗,m) is increasing in N
at the optimal N∗ because
∂
∂N
R∗ (N∗,m) = K − m
2
2γN∗2
= K
(
1− 1
2γ tm − 1
)
> 0
This means that the relationship between N∗ and R∗ is increasing for a given m.
Now, as R∗ (N∗ (m) ,m) is increasing because
dR∗ (N∗ (m) ,m)
dm
=
∂R∗ (N∗,m)
∂N
∂N∗
∂m
+
∂R∗ (N∗,m)
∂m
> 0
since
∂N∗
∂m
=
t− mγ
2
√
mtK
(
1− m2tγ
) > 0
and
∂R∗ (N∗,m)
∂m
=
m
γN∗
> 0
we can define m(R∗) as the inverse of R∗ (N∗ (m) ,m). The function m(R∗) is increasing in R∗ and
we thus have that∂N
∗
∂R∗ =
∂N∗
∂m
∂m
∂R∗ > 0.
It follows therefore that the number of equilibrium firms will also be an increasing function of total
market revenue.
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10 Appendix 2:
Table A1: First stage Regressions
Part I First Stage OLS
(1) (2) (3) (4) (5)
N tc N
t
c N
t
c′ N
t
c′ N
t
c′
Exogenous Variables
ATC 1 Dummies
ATC=A -671,704 717,025 -148,967 -153,311 100,283
(451,203) (416,881) (95,638) (93,969) (72,699)
ATC=J 1.254e+06 205,389 849,167*** 723,041*** -454,158***
(821,051) (537,990) (68,507) (71,614) (63,226)
ATC=L -546,485 -3.801e+06 -575,018*** -573,789*** 135,752***
(771,007) (2.211e+06) (50,796) (49,073) (42,162)
ATC=P -2.239e+06*
(1.187e+06)
ATC=B 2.083e+06** 2.003e+06*** 1.686e+06*** 1.444e+06*** 1.392e+06***
(754,732) (362,185) (100,290) (106,505) (74,399)
ATC=C 5.003e+06*** 506,955 -300,247* -289,961 -439,992***
(937,328) (338,806) (163,582) (175,303) (96,491)
ATC=D -1.520e+06* -367,490 60,830 51,564 -130,306*
(757,720) (564,292) (62,172) (59,405) (72,048)
ATC=G 138,386 175,317 654,693*** 640,614*** 334,121
(504,961) (645,072) (108,245) (108,539) (197,568)
ATC=M 981,497 -116,282 220,161* 182,896 -183,162**
(763,029) (330,478) (114,200) (118,717) (60,174)
ATC=N -395,630 1.269e+06 181,970** 177,085** -76,545
(714,891) (1.762e+06) (69,962) (68,877) (95,652)
ATC=R -2.723e+06*** -459,268 -201,126 -212,768 -154,221
(555,035) (830,902) (166,551) (168,083) (95,846)
ATC=H -716,467 3.279e+06 -72,251 -83,674 -71,128
(538,355) (5.187e+06) (97,227) (110,306) (59,435)
Note: All standard errors (shown in brackets) are clustered at the ATC-1 level. Time dummies included
***, **, * means significance at 1%, 5 % and 10% levels
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Table A1 - Continued 1
Part II First Stage OLS
(1) (2) (3) (4) (5)
N tc N
t
c N
t
c′ N
t
c′ N
t
c′
Excluded IVs
Male population 0.109**
Female population -0.108*
Nb of Deaths -4.135***
Nb of Male Deaths 8.380***
GDP 6.31e-08
Observations 74 74 231 231 231
R-squared 0.800 0.971 0.435 0.421 0.550
IVs A D B C D
Test Excluded. IVs
F test 60.80 46.61 886.4 1044 40.25
P value 4.19e-08 1.90e-07 0 0 4.32e-07
Excluded IVs
Male Pop Above 50 in countries
served by drugs of own ATC-2 level times ATC-1 dummy
Male Pop Above 50*ATC=A -0.274** 0.0389***
Male Pop Above 50*ATC=J -0.193 0.0497***
Male Pop Above 50*ATC=L 0.121 0.108***
Male Pop Above 50*ATC=B 0.930*** 0.0619*
Male Pop Above 50*ATC=C 1.297*** 0.0697***
Male Pop Above 50*ATC=D 0.0914 0.0326
Male Pop Above 50*ATC=G 0.317 0.0694***
Male Pop Above 50*ATC=M 0.142 0.220***
Male Pop Above 50*ATC=N -0.0133 0.0272**
Male Pop Above 50*ATC=R -0.0844 0.0666***
Male Pop Above 50*ATC=S -0.105 -0.0316
Male Pop Above 50*ATC=H -0.453 0.0265
Excluded IVs
Female Pop Above 50 in countries
served by drugs of own ATC-2 level times ATC-1 dummy
Female Pop Above 50*ATC=A 0.184** -0.0366***
Female Pop Above 50*ATC=J 0.246 -0.0198*
Female Pop Above 50*ATC=L -0.241 -0.0889***
Female Pop Above 50*ATC=P 0.000752 -0.00666
Female Pop Above 50*ATC=B -0.965*** -0.0883**
Female Pop Above 50*ATC=C -1.137*** -0.0551***
Female Pop Above 50*ATC=D -0.0902 -0.0305
Female Pop Above 50*ATC=G -0.269 -0.0593***
Female Pop Above 50*ATC=M -0.146* -0.192***
Female Pop Above 50*ATC=N 0.0261 -0.0262**
Female Pop Above 50*ATC=R 0.0928 -0.0564***
Female Pop Above 50*ATC=S 0.0882 0.0352
Female Pop Above 50*ATC=H 0.440 -0.0208
Note: All standard errors (not shown) are clustered at the ATC-1 level.
***, **, * means significance at 1%, 5 % and 10% levels
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Table A1 - Continued 2
Part III First Stage OLS
(1) (2) (3) (4) (5)
N tc N
t
c N
t
c′ N
t
c′ N
t
c′
Excluded IVs
GDP per capita in countries
served by drugs of own ATC-2 level times ATC-1 dummy
GDP per capita * ATC=A 3.06e-07*** 1.72e-08***
GDP per capita * ATC=J -4.00e-07*** -1.12e-07***
GDP per capita * ATC=L 8.31e-07** -1.12e-08
GDP per capita * ATC=P -1.22e-08 2.91e-08
GDP per capita * ATC=B 8.78e-07*** 1.98e-07***
GDP per capita * ATC=C 9.15e-08** -2.24e-08
GDP per capita * ATC=D 6.09e-08 1.25e-08**
GDP per capita * ATC=G -3.78e-08 -4.82e-09
GDP per capita * ATC=M 1.62e-07*** 1.29e-08**
GDP per capita * ATC=N -8.47e-08 1.59e-08*
GDP per capita * ATC=R -9.08e-08 -6.93e-09**
GDP per capita * ATC=S 2.21e-08 -4.05e-08**
GDP per capita * ATC=H -2.90e-07 -1.11e-08
Observations 74 74 231 231 231
R-squared 0.800 0.971 0.435 0.421 0.550
IVs A D B C D
Test Excluded. IVs
F test 60.80 46.61 886.4 1044 40.25
P value 4.19e-08 1.90e-07 0 0 4.32e-07
Excluded IVs
GDP per capita in countries
served by drugs of own ATC-1 level times ATC-1 dummy
GDP per capita * ATC=A 1.74e-08*** 1.62e-08**
GDP per capita * ATC=J -1.27e-07*** -1.09e-07***
GDP per capita * ATC=L 4.08e-08*** 3.84e-08***
GDP per capita * ATC=P 5.18e-08 5.10e-08
GDP per capita * ATC=B 6.68e-07*** 5.80e-07***
GDP per capita * ATC=C -3.02e-08*** -2.96e-08***
GDP per capita * ATC=D 1.03e-08 9.22e-09
GDP per capita * ATC=G -1.27e-08* -1.28e-08**
GDP per capita * ATC=M -2.50e-08*** -2.65e-08***
GDP per capita * ATC=N 1.86e-09 8.16e-10
GDP per capita * ATC=R -1.28e-08** -1.58e-08***
GDP per capita * ATC=S 1.29e-08 1.17e-08
GDP per capita * ATC=H -1.67e-08 -1.95e-08
Note: All standard errors (not shown) are clustered at the ATC-1 level.
***, **, * means significance at 1%, 5 % and 10% levels
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Table A1 - Continued 3
Part IV First Stage OLS
(1) (2) (3) (4) (5)
N tc N
t
c N
t
c′ N
t
c′ N
t
c′
Excluded IVs
Pop Above 50 in countries
served by drugs of own ATC-1 level times ATC-1 dummy
Pop Above 50 * ATC=A -0.00131**
Pop Above 50 * ATC=J 0.0123***
Pop Above 50 * ATC=L -0.00234***
Pop Above 50 * ATC=P -0.00572
Pop Above 50 * ATC=B -0.0648***
Pop Above 50 * ATC=C 0.00334***
Pop Above 50 * ATC=D -0.00100
Pop Above 50 * ATC=G 0.000935
Pop Above 50 * ATC=M 0.00277***
Pop Above 50 * ATC=N -0.000140
Pop Above 50 * ATC=R 0.00159***
Pop Above 50 * ATC=S -0.00110
Pop Above 50 * ATC=H 0.00183
Excluded IVs
Male pop Above 50 in countries
served by drugs of own ATC-1 level times ATC-1 dummy
Male Pop Above 50*ATC=A -0.00259**
Male Pop Above 50*ATC=J 0.0229***
Male Pop Above 50*ATC=L -0.00457***
Male Pop Above 50*ATC=P -0.0123
Male Pop Above 50*ATC=B -0.121***
Male Pop Above 50*ATC=C 0.00702***
Male Pop Above 50*ATC=D -0.00196
Male Pop Above 50*ATC=G 0.00203
Male Pop Above 50*ATC=M 0.00627***
Male Pop Above 50*ATC=N -0.000102
Male Pop Above 50*ATC=R 0.00399***
Male Pop Above 50*ATC=S -0.00215
Male Pop Above 50*ATC=H 0.00452
Observations 74 74 231 231 231
R-squared 0.800 0.971 0.435 0.421 0.550
IVs A D B C D
Test Excluded. IVs
F test 60.80 46.61 886.4 1044 40.25
P value 4.19e-08 1.90e-07 0 0 4.32e-07
Note: All standard errors (not shown) are clustered at the ATC-1 level.
***, **, * means significance at 1%, 5 % and 10% levels
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Figure 1: Total Revenue and New Chemical Entities per 1-digit ATC class
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Figure 2: Means of Revenue by Patent Age for Each ATC-1
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